Long-term efficacy and safety of Oxcarbazepine (OXC) in clinical practice were evaluated on 160 epileptic patients, over a mean period of two years and eight months. Both patients received OXC in monotherapy and in add-on and showed either maintenance (75.65%) or an improvement (21.25%) in seizures control. Overall, Oxcarbazepine was well tolerated, with 9.03% of patients experiencing adverse events similar to those previously reported.
